KDRA (Korea Drug Research Assosiation) and Kairos sign MOU to strengthen global collaboration for the Korean biopharma industry
Korea Drug Research Association (KDRA) is delighted to announce it has signed a Memorandum of Understanding (MOU) with the Kairos Bioconsulting LLC (Kairos). This MOU was signed by Jaechun Yeo, Director of KDRA and Steven Chang, CFO of Kairos, during an event 29th July at Seoul, South Korea.
The main points of the agreements are △ Cooperation in consulting and consulting for overseas technology transfer and investment attraction for union members and domestic bio-health companies to advance into overseas markets such as the US and Europe △ Business development for promising technologies/items owned by union members and domestic bio-health companies Strategic advisory consulting cooperation △ mutual information exchange necessary for business cooperation and support △ other tasks recognized by mutual cooperation according to the purpose of the agreement.
An official from the KDRA said “The demand for technologies/items developed by domestic bio-health companies to enter the global market is continuously increasing and with KDRA’s new collaboration with Kairos we will be able to assist even more companies and bring the technology innovations of the Korean biotech sector to new audiences globally.”
The Korea Drug Research Association (KDRA) is a representative organization of the domestic R&D-focused pharmaceutical and bio-health industry that was officially launched in 1986 as an organization under the Ministry of Science and ICT. It is playing a central role in open innovation and cooperation between domestic and foreign industry, academia, research, military, venture, and start-ups. It is carrying out various projects such as policy research and innovation statistics construction projects for industrial development. It currently has over 520 member companies
For more details, visit http://www.kdra.or.kr
About Kairos Bioconsulting
Kairos is a business development (BD) consulting firm located in Maryland, United States. BD experts with an average pharmaceutical career of more than 15 years based on a number of actual business experiences and success stories are conducting a series of business developments related to strategic alliances (licensing, joint development, joint research, etc.) for overseas expansion of new drug projects owned by bio-health companies.
For more details, visit http://www.kairosbt.com